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Suggested New Upper Limit of
Physiologic Cardiac Hypertrophy
Determined in Japanese Ultramarathon
Runners Must Be Interpreted Cautiously
With great interest and surprise we read the study by Nagashima
et al. (1). The researchers report that 11% of the participants (33
of 291) had a left ventricular end-diastolic diameter (Dd) larger
than 70 mm. In addition, further extraordinary values for the
end-Dd (mean value, 61.8  6.9 mm; range, 42 to 75 mm), the
end-systolic diameter (mean value, 39.6 6.9 mm; range, 23 to 55
mm), and the intraventricular septal thickness (range, 5 to 19 mm)
are presented, which are in great contrast to results reported
previously (2–5).
The data presented are even more surprising when normalized
to the body surface area (BSA; mean value, 1.66  0.1 m2),
resulting in an unbelievable mean Dd-to-BSA ratio of approxi-
mately 37 mm/m2. Such a high value seems unrealistic, especially
when compared with the data of Pelliccia et al. (3), who found the
highest mean Dd-to-BSA ratio of about 31 mm/m2 in healthy
endurance athletes competing at national and international levels
(59 track-and-field athletes, 49 cyclists, and 41 cross-country
skiers). Also, the range of the intraventricular septal thickness (5 to
19 mm) is suspicious for at least some pathologically hypertrophied
hearts. Consequently, based on the data of previous reports (2–6),
hearts with an end-Dd 60 mm or an intraventricular septal
thickness 13 mm in athletes with a BSA 1.82 m2 are highly
suspicious for pathologic hypertrophy (2) and would have required
further cardiologic examinations to confirm the statement of a
physiologic hypertrophy. Therefore, the data presented by Na-
gashima et al. (1) suggesting a new upper limit of physiologic
cardiac hypertrophy may lead to confusion and to misinterpreta-
tions in daily routine (diagnosis of athlete’s heart instead of
pathologic hypertrophy), and put athletes at an avoidable risk.
The main confounding variable of the study (1) seems to be the
age of the subjects (mean age, 41.8  9.7 years; range, 20 to 73
years). As it is well known that the incidence of cardiovascular
diseases rises with age (especially above 35 to 40 years) (7),
cardiovascular diseases in the participants should have been ex-
cluded by cardiologic examinations. It is not sufficient to assess the
state of an athlete’s health by taking only the resting blood pressure
or replies to questionnaires (1). Furthermore, relevant additional
examinations should have been performed, and important param-
eters should have been given in the study: ejection fraction to
describe the systolic function; E/A ratio to evaluate the diastolic
function; Doppler-echocardiography to exclude valvular diseases
resulting in pathologic ventricular overload and dilation; 12-lead
electrocardiogram at rest and exercise (including blood pressure
measurements) to detect possible coronary artery disease or
exercise-related hypertension; and spiroergometry to obtain max-
imal oxygen consumption, which describes the state of physical
fitness and is closely related to cardiac dimensions [8–10]. More-
over, the convention of echocardiographic measures is not given
(Penn or American Society of Echocardiography convention
[11,12]).
In conclusion, it seems that the study by Nagashima and
co-workers does not define a new upper limit (which now would be
70 mm or even 75 mm, when the 95% confidence interval for the
left ventricular end-Dd is calculated), but a wrong upper limit of
physiologic cardiac hypertrophy.
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REPLY
The aim of our study (1) was that: 1) our cases include more of the
larger cardiac chambers than had ever been previously reported;
and 2) larger cardiac chambers are not significantly related to body
surface area (BSA) but to the extent of the monthly running.
The main insistence of the comment from Dr. Whalley et al.
seems to be in the inappropriateness of using BSA as an index of
body size. We did not describe the left ventricular mass but the
chamber size. This was done to compare previous reports on
cardiac size. Lean body mass was not measured in our study
because of the limitation of methodology. Milliken et al. (2)
observed that the cardiomegaly observed in highly trained athletes
was much higher than in non-athletes and its grade was above the
level of correction by the body size. We agree about the importance
of evaluation through accurate correction of body size among the
non-athletic general population, but it seems that the choice of
BSA or lean body mass is not critical for evaluating cardiomegaly
in highly trained athletes. Our subjects included an exclusively
homogeneous group of long-distance runners having lean body
composition. Hence, the use of BSA as the index of body size
could be justified, and it was concluded that the sole determining
factor of cardiac size in athletes is the intensity of training.
Whether this cardiomegaly is pathological or physiological re-
mains unclarified, as described in our Study Limitations section.
Further follow-up study is now being conducted.
We understood the questions raised by Drs. Kasikcioglu and
Akhan as to 1) how many investigators participated in the study,
and 2) that pathological hypertrophy could be included. Concern-
ing the first question, both the examination and the measurement
of echocardiograms were performed solely by J. Nagashima, MD,
a certified Fellow of the Japanese Society of Ultrasonics in
Medicine. Gordon et al. (3) concluded that intraobserver variabil-
ity was minimal, but interobserver and beat-to-beat variability
levels were of sufficient magnitude to suggest that serial measure-
ments on a given subject be made, ideally by a single person, and
that several cycles be averaged for a given measurement.
Concerning the second question, our entry conditions in this
study were exclusion of subjects with hypertension or a positive
reply to Revised Physical Activity Readiness Questionnaire. We
found six cases showed more than 16 mm in the inter-ventricular
septal thickness; the minimum diameter of left ventricle was 58
mm, and the ejection fraction was above 62%. It seems different
from the conventional type of hypertrophic cardiomyopathy
(HCM) because of the absence of a lessened size of the left
ventricular (LV) chamber and also different from the dilated phase
of HCM because of the presence of normal LV contractility (4).
These might be considered to be HCM modified by the effect of
intensive endurance training, but the precise determination of
etiology remains undefined at the present time.
The questions raised by Dr. Scharhag et al. concern 1) end-
diastolic diameter (Dd) to BSA ratios that are much larger than in
previous reports. Hence, pathological hypertrophy might be in-
cluded; and 2) the precise method of echocardiography is not
described. We already addressed these issues in the reply to the
query by Dr. Kasikcioglu et al. Regarding the Dd-to-BSA ratio,
we already stated in our discussion that “Compared with the
subjects of previous reports, the BSA of our subjects was signifi-
cantly smaller, so a larger cardiac load per unit of body size may
have been related to our findings.” One reason for obtaining so
high a value of Dd-to-BSA ratio might be due to the significantly
small BSA in our subjects compared to the previous reports. Dr.
Scharhag’s criticism concerns the insufficient exclusion of cardiac
abnormality. We could not completely exclude the presence of
possible latent coronary artery disease, as he points out. However,
all our subjects are apparently quite healthy individuals who could
perform the highly severe daily training for a long time and finish
the race within the time limit of 14 h, showing their high
endurance ability.
Finally, besides the measurements described in the text, ejection
fractions calculated using Teichholz’s method were within normal
limits in all subjects. We believe that a small grade of coronary
artery disease, which could not be detected by routine measure-
ments, could not influence the results of our study. But we do
recognize the importance of the questions raised, and hence we
want to show the longitudinal follow-up study in the future.
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